VAT N° 01537970525
About us
Our name
UCme BioScience is a spin-off of the University of Siena and was founded with the aim of developing new therapeutic solutions based on the know-how of our research in the field of angiogenesis. The company's name reflects our inspiring mission: to save the vision of patients affected by neovascular retinopathies. However, the inhibition of angiogenesis also has important applications in cancer therapy.
Our lead product in preclinical development is the monoclonal antibody 4E1 directed against the human receptor CD93, a novel and promising target for anti-angiogenic therapy.
Maurizio Orlandini
Mario Lorenzoni
Chief Development Officer
Molecular biologist
Chief Executive Officer
Biotech and Pharmaceutical company manager
Associate professor of Molecular Biology at the University of Siena
Gian Marco Tosi
Federico Galvagni
Chief Clinical Officer
Ophthalmologist
Chief Researcher Officer
Molecular biologist
Head of the Ophthalmology Unit - Siena Hospital
Full professor of Ophthalmology at the University of Siena
Associate professor of Molecular Biology at the University of Siena
Accelerator incubator of Fondazione Golinelli
G-Factor is a reactive environment whose aim is to support new entrepreneurs and researchers with high entrepreneurial potential to become companies able to successfully establish themselves in the market, creating replicable and scalable models.